pharma · Multiple Myeloma · Ovarian Cancer · CASIF
CASI Pharmaceuticals
CASI Pharmaceuticals is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker CASIF. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer, Advanced Cancer, Recurren
601 Gateway Blvd, San Francisco, CA 94080, US HQ
44 Employees
Public company Type
CASIF · NYSE Ticker
Company details
- Status
- Public
- HQ
- 601 Gateway Blvd, San Francisco, CA 94080, US
- Employees
- 44
- Programs
- 22
- Drugs
- 11
- Patents
- 2
ENMD-2076
Phase 2 · small molecule · Advanced Adult Hepatocellular Carcinoma
ENMD-2076 for Advanced Adult Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 2076-CL-006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CASI Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Adult Hepatocellular Carcinoma
- Status
- completed
- Trials
- 1